Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51862-0447-18 51862-0447 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug 3, 2016 May 31, 2021 In Use
00002-4165-79 00002-4165 Raloxifene Hydrochloride Evista 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan 6, 1998 Jan 25, 2011 No Longer Used
63629-4413-03 63629-4413 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Mar 7, 2011 In Use
65862-0709-30 65862-0709 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug 28, 2015 In Use
54868-4287-00 54868-4287 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan 17, 2005 In Use
51862-0643-30 51862-0643 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug 27, 2021 In Use
68382-0827-10 68382-0827 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan 3, 2018 In Use
70771-1185-01 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan 3, 2018 In Use
00179-0220-70 00179-0220 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Oct 12, 2016 Mar 31, 2018 In Use
79802-0200-30 79802-0200 belumosudil Rezurock 200.0 mg/1 Chemotherapy Rho Kinase Inhibitor ROCK 1, ROCK2 Oral Jul 16, 2021 In Use
75929-0174-03 75929-0174 Belumosudil Rezurock 200.0 mg/1 Chemotherapy Rho Kinase Inhibitor ROCK 1, ROCK2 Oral Jul 16, 2021 In Use
00024-5841-01 00024-5841 ziv-Aflibercept Zaltrap 200.0 mg/8mL, 200.0 mg/8mL Chemotherapy Recombinant Fusion Protein VEGF-IgG1 Intravenous Aug 3, 2012 In Use
00024-5840-03 00024-5840 ziv-Aflibercept Zaltrap 100.0 mg/4mL Chemotherapy Recombinant Fusion Protein VEGF-IgG1 Intravenous Aug 3, 2012 Nov 27, 2019 In Use
00024-5840-01 00024-5840 ziv-Aflibercept Zaltrap 100.0 mg/4mL Chemotherapy Recombinant Fusion Protein VEGF-IgG1 Intravenous Aug 3, 2012 In Use
85219-0101-01 85219-0101 Daraxonrasib RASONQUE 100.0 mg/1 Chemotherapy RAS Inhibitor KRAS, NRAS, HRAS Oral Aug 26, 2026 In Use
55513-0488-24 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
85219-0104-01 85219-0104 Daraxonrasib RASONQUE 150.0 mg/1 Chemotherapy RAS Inhibitor KRAS, NRAS, HRAS Oral Aug 26, 2026 In Use
55513-0488-02 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0504-50 55513-0504 Sotorasib LUMAKRAS 320.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral Feb 2, 2023 In Use
55513-0512-60 55513-0512 Sotorasib LUMAKRAS 240.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral Jun 27, 2024 In Use
80739-0812-18 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec 12, 2022 In Use
80739-0812-12 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec 12, 2022 In Use
55513-0488-96 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
51808-0119-01 51808-0119 I 131 Mini I 131 Mini 500.0 mCi/1 Chemotherapy Radiopharmaceutical Iodine 131 Oral May 23, 2012 In Use
11994-0016-01 11994-0016 samarium Sm 153 lexidronam Quadramet 50.0 mCi/mL Ancillary Therapy Radiopharmaceutical Samarium Sm 153 Intravenous May 19, 1997 In Use

Found 12611 results — Export these results